Canada markets closed

XOMA Corporation (XOMA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
25.41+0.05 (+0.20%)
At close: 04:00PM EDT
25.41 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close25.36
Open25.08
Bid0.00 x 0
Ask0.00 x 0
Day's Range25.08 - 25.50
52 Week Range13.48 - 27.00
Volume5,828
Avg. Volume18,571
Market Cap295.645M
Beta (5Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.16 (8.49%)
Ex-Dividend DateApr 02, 2024
1y Target EstN/A
All
News
  • GlobeNewswire

    XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

    XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $9 million milestone related to the U.S. Food and Drug Administration’s (FDA) approval of Day One Biopharmaceuticals’

  • PR Newswire

    Actym Therapeutics Appoints Thomas Smart as CEO

    Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical eval

  • GlobeNewswire

    XOMA Corporation Announces Closing of Tender Offer

    Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value RightEMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ: KN